



---

**PRESS RELEASE**

BSE: 506690	NSE: UNICHEMLAB	Reuters: UNLB.BO	Bloomberg: UN@IN
-------------	-----------------	------------------	------------------

Mumbai, January 20, 2010

**Unichem Laboratories receives ANDA approval from USFDA for Hydrochlorothiazide Capsules**

Unichem laboratories Limited pleased to announce that it has received ANDA approval from the United States Food and Drug Administration (U.S. FDA) for Hydrochlorothiazide Capsules in the strengths of 12.5 mg

Hydrochlorothiazide is a thiazide diuretic used in the management of edema and hypertension. In hypertension, thiazide diuretics are often used as initial therapy, either alone or in combination with other agents. Hydrochlorothiazide's innovator is Novartis-Global and appears world-wide under the brand names: Esidrix, HydroDIURIL, Microzide and Oretic

**About Unichem Laboratories Limited.**

Unichem Laboratories Limited is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India and several other markets across the world. In India, the company is a leader in niche therapy areas of cardiology, neurology, orthopedics and anti-infectives. The company has strong skills in product development, process chemistry and manufacturing of complex API as well as dosage forms. More information about the company can be found at [www.unichemindia.com](http://www.unichemindia.com).

**Contacts:**

Mr. K Subharaman  
Tel: +912266888404  
Cell: +919833031121  
e-Mail: [subharamank@unichemindia.com](mailto:subharamank@unichemindia.com)

Mr. Rakesh Parikh  
Tel: +912266888414  
Cell: +919892925555  
e-Mail: [rparikh@unichemindia.com](mailto:rparikh@unichemindia.com)

Mr. M Gundu Rao  
Tel: +912266888380  
Cell: +919820228944  
e-Mail: [gundurao@unichemindia.com](mailto:gundurao@unichemindia.com)

---

*This press release includes forward-looking statements. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.*

---

-oOo-